Pallas Capital Advisors LLC Purchases 3,897 Shares of Zoetis Inc. $ZTS

Key Points

• Pallas Capital Advisors LLC increased its stake in Zoetis Inc. by 45.4%, acquiring an additional 3,897 shares, bringing their total holdings to 12,488 shares worth approximately $1.95 million.
• Despite recent fluctuations, Zoetis has a consensus rating of "Moderate Buy", with a consensus target price of $200.88 as analysts express varied outlooks.
• Zoetis reported $1.76 earnings per share for the last quarter, exceeding expectations, and experienced 4.2% revenue growth year-over-year, indicating strong performance.

Pallas Capital Advisors LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 45.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,488 shares of the company's stock after acquiring an additional 3,897 shares during the period. Pallas Capital Advisors LLC's holdings in Zoetis were worth $1,947,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ZTS. Baron Wealth Management LLC grew its position in Zoetis by 37.7% during the 2nd quarter. Baron Wealth Management LLC now owns 2,497 shares of the company's stock worth $389,000 after purchasing an additional 684 shares during the last quarter. Aaron Wealth Advisors LLC grew its position in Zoetis by 5.6% in the 2nd quarter. Aaron Wealth Advisors LLC now owns 3,446 shares of the company's stock valued at $537,000 after buying an additional 182 shares during the last quarter. Balefire LLC acquired a new position in Zoetis in the 2nd quarter valued at about $371,000. New England Research & Management Inc. boosted its holdings in Zoetis by 0.7% in the 2nd quarter. New England Research & Management Inc. now owns 24,788 shares of the company's stock worth $3,866,000 after acquiring an additional 170 shares during the period. Finally, Krilogy Financial LLC increased its position in Zoetis by 49.4% in the second quarter. Krilogy Financial LLC now owns 17,738 shares of the company's stock worth $2,766,000 after buying an additional 5,864 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Piper Sandler increased their price objective on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Argus restated a "buy" rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Trading Down 0.9%

Shares of Zoetis stock traded down $1.28 during trading on Friday, hitting $145.82. The stock had a trading volume of 4,455,824 shares, compared to its average volume of 2,273,605. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $64.63 billion, a PE ratio of 25.10, a P/E/G ratio of 2.34 and a beta of 0.89. The stock has a 50 day simple moving average of $151.25 and a 200 day simple moving average of $156.52. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $197.51.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.